Clinical summary
Summary
This study consists of two parts. In Part 1, participants with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC will be randomly allocated into one of three cohorts. Each cohort will receive a different dose level of immunotherapy (INCB099280). In Part 2, the dose level identified as being the safest and most effective in Part 1 will be expanded to enrol additional participants with metastatic cSCC and locally advanced cSCC.Age
18+
More information
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Commercial Sponsor
Incyte Corporation
Scientific Title
A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Squamous Cell Carcinoma